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Abstract. This is a case report of a 40-year-old woman
who, after conservative breast cancer treatment, developed
a HER2 positive solitary brain metastasis in the left temporal
lobe, without extracranial disease. She underwent surgery
resection followed by stereotactic radiotherapy and, because
of early brain progression, she was submitted to the first line
therapy with pertuzumab, trastuzumab and weekly paclitaxel.
After six months of treatment, a brain magnetic resonance
imaging revealed a complete disappearance of brain
recurrence, which persisted for more than 24 months. 
In human epidermal growth factor receptor 2 (HER2)-
expressing breast cancer (BC) subtype the incidence of brain
metastases (BM) after the diagnosis of the primary tumor is
between 3.2% and 3.7% and significantly raises (30-50%) in
patients who do not receive adjuvant anti-HER2 monoclonal
antibody trastuzumab (T) (1, 2). 
It has been reported that, although T significantly improves
the prognosis of patients with HER2-positive advanced BC
(3), the overall survival from the time of diagnosis in women
with BC and BM (BCBM) is less than 1.2 years (4, 5). 
Recently, according to the Cleopatra trial, the combination
of pertuzumab (P) and T plus docetaxel showed a significant
impact on progression-free survival and overall survival in
HER2-positive metastatic BC patients (6). Although this trial
did not enroll BCBM patients, an exploratory analysis
showed that time to BM development as the first site of
disease progression and overall survival were significantly
prolonged in patients receiving P plus T vs. T alone
(respectively, 15 vs. 11.9 months p=0.0049, and 34.4 vs. 26.3
months p=0.11) (7). These findings are one of the main
reasons to treat BCBM patients with the dual blockade plus
taxanes as a first-line option.
This is a case report of a HER2-positive BC woman with
BM as a unique site of disease progression. This patient
experienced an impressive clinical benefit by anti-HER2 dual
blockade.
Case Report
On November 2009, a 40-year old woman presented with a
20×20 mm mass in her left breast, with palpable fixed
axillary nodes. A core needle biopsy of the breast tumor
revealed an invasive ductal carcinoma and the fine needle
aspiration of an axillary node documented metastasis from
BC. Total body Computed Tomography (CT scan) showed
absence of distant metastases. The clinical stage at diagnosis
was cT2N2M0. The immunohistochemical analysis revealed
that the tumor expressed estrogen receptor (ER, 50%), but
not progesterone receptor (PGR, 0%) and HER2 (0%). 
She received neo-adjuvant chemotherapy including 4
courses of 3-weekly doxorubicin 60 mg/m2 plus
cyclophosphamide 600 mg/m2 followed by 4 courses of 3-
weekly docetaxel 100 mg/m2. A radical mastectomy with
axillary node dissection was subsequently performed. The
histological examination revealed a pathological partial
response with residual ductal infiltrating carcinoma in the
left breast and absence of metastases in the axillary nodes
(pT1bN0). The biological profile was: ER 55%, PgR 25%,
HER2-negative and Ki-67 15%. The patient received anti-
estrogen treatment with tamoxifen plus triptorelin until
November 2014.
On October 2015, after persistent headache, she
underwent total body CT scan and brain magnetic resonance
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imaging (MRI): a single BM in the left temporal lobe was
discovered, without extracranial diffusion of the disease. A
surgical resection of the right temporal metastasis was
performed and the histological examination confirmed the
origin from breast carcinoma, with the following biological
features: ER 55%, PGR 20%, HER2 2+, SISH amplified. On
November 2015, the woman received 4 courses of
stereotactic brain radiotherapy in the site of surgery. After 40
days from surgery, the brain MRI revealed the presence of a
small nodular recurrence close to the surgical cavity (Figure
1A and B). The patient did not complain of any neurological
symptoms. Again, the total body CT scan showed a absence
of extra-cranial diffusion of the disease.
Between December 2015 and May 2016, the patient
received 8 cycles of T (8 mg/kg iv loading dose followed by 6
mg/kg every three weeks), P (840 mg iv loading dose followed
by 420 mg every three weeks) and weekly paclitaxel (80
mg/m2) over a period of six months for a total of 24 weekly
administrations. The therapy was well tolerated without serious
adverse events. During the course of combined treatment, the
patient had brain MRI every 3 months which showed a
progressive shrinkage of BM (Figure 2A and B), while the CT
scan did not document extracranial metastases. From June
2016 the patient has been receiving maintenance treatment with
the dual monoclonal blockade. She has an optimal performance
status, without any neurological symptom. The last brain MRI
has confirmed the persistence of a complete response obtained
from May 2016 (Figure 2C and D). 
Discussion
The management of patients with BCBM include both
surgery and radiotherapy (RT), which are the standard first-
line modalities for treatment of BM.
Whole brain radiotherapy (WBRT) is recommended for the
treatment of multiple BM while stereotactic radiosurgery (SRS)
is an option in patients with oligometastatic disease.
Systemic therapy plus T, administered after WBRT,
appears to have a positive impact on survival among HER2
positive BC patients with BM, probably due to the control
of extracranial disease (8). 
Pertuzumab is a humanized monoclonal antibody which
binds to the subdomain II dimerization arm of HER2
receptor and inhibits the interaction of HER2 with its main
co-receptor HER3 (9). As well as T, P stimulates antibody-
dependent and cell-mediated cytotoxicity. In HER2-positive
preclinical tumor models the combination of T plus P
resulted in greater antitumor inhibition than either agent
alone (10). On this basis the efficacy and safety of P plus T
were evaluated in phase II and III clinical trials carried out
in patients with HER2-positive metastatic BC (11-13). The
impressive findings of the registrative CLEOPATRA study
with the significantly prolonged progression free survival
and overall survival in favour of dual blockade with P+T and
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Figure 1. MRI images with SE T1 after gadolinium in axial (A) and
coronal (B) planes show peripherally at surgical cavity the presence of
small nodular lesions (arrows) in relation to recurrence.
Figure 2. MRI images with SE T1 after gadolinium in axial (A) and
coronal (B) planes after 12 months and in axial (C) and coronal (D)
planes after 24 months, show disappearance of the nodular lesions, in
relation to complete response to treatment.
docetaxel doubtless defined the standard of care in first-line
metastatic BC (12). 
Recently, Dang et al. demonstrated that paclitaxel given
once per week with T and P is highly effective and well-
tolerated and could be an alternative to docetaxel-based
combination therapy in first and second line setting (14). 
No data are available on the ability of P to cross the blood
brain barrier (BBB), but the delay in the involvement of the
central nervous system, as shown by Swain et al., leads to
the hypothesis of a possible synergistic activity of P plus T
on central nervous system (CNS) metastases (7). 
In the second setting, recent trials evaluated BMBC
patient’s outcome with HER2 directed agents after T failure.
Trastuzumab emtansine (T-DM1) is an antibody-drug
conjugate of the anti-microtubule emtansine and T. 
In the EMILIA study, in which T-DM1 was compared
with lapatinib plus capecitabine in advanced HER2 positive
metastatic BC pre-treated with Trastuzumab, TDM-1
conferred a prolonged overall survival also in patients with
pre-existing BCBM (26.8 vs. 12.9 months, p=0.008) (15).
The activity of other HER2-directed drugs (lapatinib and
neratinib) have been also investigated in BMBC patients. 
Lapatinib, a reversible dual inhibitor of the intracellular
tyrosine kinase domain of HER1 and HER2, is expected to
cross the BBB due to its very low molecular weight. Its
efficacy, has been investigated in combination with
capecitabine in a small cohort of 44 HER2-positive untreated
metastatic BMBC patients. In this single arm phase II trial
(Landscape study), objective CNS response rate was of 65.9%
(95%CI=50.1-79.5) and all were partial responses (16).
In the CEREBEL phase III trial, 540 metastatic BC
patients were randomly assigned (1:1) to receive lapatinib-
capecitabine or trastuzumab-capecitabine; the trial was not
conclusive in terms of the incidence of CNS metastases as
first site of relapse which was the primary end point of the
study (3% in the patients in the lapatinib-capecitabine arm
and 5% in the T-capecitabine arm, 21.6%; 95%CI=22-25%;
p=5.360) (17).
Neratinib, an irreversible pan-ERBB tyrosine kinase
inhibitor, in combination with paclitaxel was recently
compared with T plus paclitaxel, as first-line treatment of
metastatic HER2-positive BC. In this randomized, controlled,
open-label trial (NEFERT-T), neratinib plus paclitaxel was
not superior to T-paclitaxel in terms of PFS [12.9 months
(95%CI=11.1-14.9) and 12.9 months (95%CI=11.1-14.8),
respectively (p=0.89)]. However, the incidence of BM was
lower (relative risk, 0.48; 95%CI=0.29-0.79; p=0.002) and
the time to CNS metastasis was delayed (HR=0.45;
95%CI=0.26-0.78; p=0 .004) in the experimental arm (18).
Despite the paucity of data available on the activity of the
new anti-HER2 compounds in the subgroup of HER2-
positive BC women who developed BM as a first and single
site of disease progression, our patient was treated with P
plus T and paclitaxel for an early brain progression after
loco-regional therapy (surgery and stereotactic radiation). A
long duration of complete response in the BM (20+ months)
was achieved. In this case, both the capacity of metastases
itself to break the BBB facilitating the entrance of
therapeutic agents and the previous surgery, which may
have induced an alteration of BBB increasing the
penetration of the two monoclonal antibodies, could explain
the success in controlling the growth of BMs (19). In
support of our findings, Mounsey et al., recently reported a
longer overall survival from BCBM diagnosis among
patients who received HER2 targeted therapy compared to
those who did not (2.1 years [95%CI=1.6-2.6] vs. 0.65 years
[95%CI=0.4-1.3; p=0.001) (20). The same positive impact
on survival was also observed among HER2-positive BC
patients who received targeted therapies after local
treatment for solitary breast cancer BM (21). Finally, our
findings could encourage clinicians to use the anti-HER2
double blockade for BMs even before loco-regional
approaches (surgery, stereotactic RT, surgery plus
stereotactic RT), especially in cases of single or oligo
asymptomatic BMs, without extracranial disease. This
therapeutic approach could help clinicians to eventually
delay toxicities deriving from loco-regional therapies, such
as (neurocognitive impairment, radionecrosis). 
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